Carcinoma, Squamous Cell
100
13
17
39
Key Insights
Highlights
Success Rate
63% trial completion
Published Results
20 trials with published results (20%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
23.0%
23 terminated out of 100 trials
62.9%
-23.6% vs benchmark
17%
17 trials in Phase 3/4
51%
20 of 39 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 39 completed trials
Clinical Trials (100)
Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa
A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
Intratumoral N17350 in Advanced Solid Tumors
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer